Research articles
ScienceAsia 49 (2023):ID 56-62 |doi:
10.2306/scienceasia1513-1874.2023.130
The role of the phosphatidylinositol 3-kinase/protein kinase B
signaling pathway in the pulmonary vascular remodeling of
pulmonary arterial hypertension in rats
Yan Duana,b, Ting Wanga,b, Shan-Shan Wuc
, Dong Liua,b, Jian Zhaoa,b, Bin Liua,b,*
ABSTRACT: This study aimed to investigate the role of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)
signaling pathway in the pulmonary vascular remodeling (PVR) of pulmonary arterial hypertension (PAH) in rats.
A PAH model in rats was established through a left pneumonectomy and monocrotaline (MCT) injection, using the
transglutaminase 2 (TG2) inhibitor cystamine dihydrochloride for intervention. Thirty healthy male Sprague Dawley
rats were randomized into a control group, a model group, and an intervention group (n = 10 for each group).
The mean pulmonary arterial pressure (mPAP) was measured in all groups after 35 days, and the right ventricular
hypertrophy index (RVHI) was calculated. Hematoxylin and eosin and lung elastic-fiber staining were used on the rats?
lung tissue in all three groups. The changes in pulmonary blood vessels and lung tissue force and the percentage of
medial hypertrophy of small pulmonary arteries (WT%), vessel wall area to total area ratio (WA%), and the neointimal
proliferation degree were observed. The Akt messenger RNA (mRNA) expression levels of lung tissues in all three
groups were measured using a real-time polymerase chain reaction (RT-PCR) assay, and the protein expression levels of
Akt and phosphorylated Akt (p-Akt) in all three groups were measured using a Western blot assay. The results indicated
that the PI3K/Akt signaling pathway might play a substantial role in inhibiting pulmonary vascular remodeling (PVR)
following intervention with a TG2 inhibitor.
Download PDF
99 Downloads 1844 Views
| a |
Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Jiangyang, Luzhou 646000 China |
| b |
Sichuan Clinical Research Center for Birth Defects, China |
| c |
Department of Emergency Medicine, West China Second Hospital of Sichuan University, Chengdu 610041 China |
* Corresponding author, E-mail: lblyfy@126.com
Received 13 Oct 2021, Accepted 27 Jun 2022
|
